IONSYS Drug Patent Profile

« Back to Dashboard

Which patents cover Ionsys, and what generic alternatives are available?

Ionsys is a drug marketed by The Medicines Co and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in IONSYS is fentanyl hydrochloride. There is one drug master file entry for this compound. Additional details are available on the fentanyl hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ionsys

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IONSYS

US Patents:	7
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	7
Patent Applications:	144
DailyMed Link:	IONSYS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IONSYS

NDA:

021338

Dosage:

SYSTEM;IONTOPHORESIS, TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IONSYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital for Special Surgery, New York	Phase 4
The Medicines Company	Phase 4
Incline Therapeutics, Inc.	Phase 3

See all IONSYS clinical trials

US Patents and Regulatory Information for IONSYS

IONSYS is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y

Expired US Patents for IONSYS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006

International Patents for IONSYS

When does loss-of-exclusivity occur for IONSYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

India

Israel

Japan

Mexico

New Zealand

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IONSYS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	234130
Austria	235284
Australia	2987692
Australia	4425489
Australia	627786
Australia	658246

Supplementary Protection Certificates for IONSYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0836511	91265	Luxembourg		91265, EXPIRES: 20210124
0836511	CA 2006 00019	Denmark		PRODUCT NAME: FENTANYL HYDROCHLORID
0836511	SPC/GB06/022	United Kingdom		PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006

IONSYS Market Dynamics, Financial Trajectory, Patent Position, and Commercial Outlook

Last updated: September 25, 2026

IONSYS was a hospital-only, patient-controlled fentanyl delivery system developed for short-term treatment of acute postoperative pain. Its commercial trajectory was limited by device recalls, manufacturing problems, hospital adoption barriers, and competition from established intravenous patient-controlled analgesia systems. The product has no meaningful current commercial market in the United States, and its historical revenue contribution to The Medicines Company was small relative to the company’s core products.

What was IONSYS and how did the product work?

IONSYS was a fentanyl hydrochloride iontophoretic transdermal system. It delivered fentanyl through intact skin using a low electrical current generated by a disposable, self-contained device.

The system was designed for adult patients in hospitals who required short-term opioid analgesia after surgery. Each activation delivered 40 micrograms of fentanyl over approximately 10 minutes. The device incorporated a lockout period to limit repeated dosing. It was intended to replace some forms of intravenous patient-controlled analgesia without requiring an indwelling intravenous line.

Product attribute	IONSYS specification
Active ingredient	Fentanyl hydrochloride
Delivery route	Iontophoretic transdermal
Primary setting	Hospital, postoperative pain
Patient population	Adults requiring short-term acute pain control
Dose per activation	40 micrograms
Administration	Patient activated
Product type	Drug-device combination
FDA pathway	New Drug Application
Original sponsor	Janssen-Ortho and related Johnson & Johnson entities
Later commercial sponsor	The Medicines Company
Current U.S. status	No active commercial market

The product’s value proposition was operational rather than pharmacological. IONSYS aimed to reduce IV-line dependence, simplify postoperative analgesia, and provide controlled patient activation. Its limitations included a narrow indication, hospital-only use, opioid safety requirements, device reliability risks, and the need for hospital staff to manage a specialized product.

When did IONSYS receive FDA approval and lose commercial exclusivity?

The FDA approved IONSYS in 2006 for the short-term management of acute postoperative pain in adult patients who required opioid analgesia in a hospital setting. The product was later removed from the U.S. market, reintroduced with a redesigned system, and withdrawn again after additional manufacturing-related problems.

Date	Event	Commercial effect
2006	FDA approval of IONSYS	Created a U.S. hospital market for patient-controlled transdermal fentanyl
2008	Product recall and commercial withdrawal	Interrupted hospital adoption and damaged confidence in the device
2011	The Medicines Company acquired Incline Therapeutics, the IONSYS developer	Shifted commercial ownership and development responsibility
2015	FDA approval of a redesigned IONSYS system	Reopened the U.S. commercial opportunity
2016	Commercial relaunch	Generated limited hospital sales
2017	Voluntary recall related to device manufacturing problems	Effectively ended the relaunch
Subsequent years	No sustained commercial re-entry	Product lost practical market relevance

IONSYS did not lose exclusivity through a conventional generic launch. Its commercial failure resulted primarily from product reliability and manufacturing issues rather than direct substitution by an approved generic IONSYS device.

FDA regulatory exclusivity also had limited long-term value. The product’s narrow hospital indication and interrupted commercialization reduced the economic benefit of any remaining regulatory protection. Once the product was recalled, patent and regulatory exclusivity no longer provided a practical commercial barrier.

What is the FDA and Orange Book status of IONSYS?

IONSYS was approved under NDA 021338. The product’s labeling identified it as a controlled-release fentanyl system for hospital use. The FDA later documented safety and manufacturing concerns involving the delivery device.

The Orange Book is not a reliable indicator of current commercial availability for IONSYS. The product is not an actively marketed branded product with a functioning generic market. Historical patent listings, if present in archival Orange Book records, do not create a current commercial opportunity unless a sponsor can obtain an approvable product, secure manufacturing capability, and establish hospital demand.

The relevant regulatory issue is therefore not simple patent expiry. A new entrant would need to address:

• Combination-product development requirements.
• Reliable dose delivery over the full labeled use period.
• Human factors and patient-use validation.
• Opioid abuse and diversion controls.
• Hospital pharmacy and nursing workflow.
• Manufacturing inspection and quality-system compliance.
• FDA requirements for a product with a prior recall history.

What patents protected IONSYS?

IONSYS relied on intellectual property covering iontophoretic drug delivery, fentanyl formulations, dosing controls, electrode systems, and device architecture. The most valuable commercial protection was likely the combination of drug delivery technology and device implementation rather than a basic fentanyl composition patent.

Fentanyl itself is an established generic active ingredient. A competitor therefore could not be blocked indefinitely from using fentanyl. The defensible elements were:

1. The iontophoretic delivery mechanism.
2. The electrode and reservoir design.
3. Dose-control and lockout features.
4. The drug-device combination.
5. Manufacturing methods for consistent transdermal delivery.
6. Clinical and human-factors data supporting hospital use.

The practical strength of this estate was constrained by the product’s commercial history. A patent portfolio can protect a device configuration, but it cannot eliminate engineering, manufacturing, regulatory, and hospital adoption risks. Patent expiry dates for individual historical IONSYS patents are less important than the absence of an active commercial product and the availability of alternative opioid-delivery technologies.

How strong was the IONSYS patent estate?

The estate was technically differentiated but commercially narrow. Its strength can be characterized as follows:

Protection category	Historical strength	Current commercial relevance
Fentanyl active ingredient	Low	Minimal, because fentanyl is generic
Iontophoretic delivery	Moderate to high	Depends on claim scope and expiration
Device architecture	Moderate	Relevant only to similar device designs
Dosing and lockout controls	Moderate	Can be designed around
Hospital method of use	Low to moderate	Limited by narrow patient population
Manufacturing know-how	Potentially high	May remain difficult to replicate
Regulatory package	Historically valuable	No current value without active commercialization

No broad patent barrier prevents companies from developing alternative hospital fentanyl delivery products. Competitors could use a different device, route of administration, formulation, or control system.

What caused the IONSYS market failure?

The primary market failure was operational reliability. IONSYS depended on a disposable electronic delivery system, making the product more complex than injectable fentanyl or conventional PCA pumps.

The principal commercial pressures were:

• A 2008 recall that interrupted market development.
• Repeated manufacturing and device-quality problems.
• Hospital reluctance to adopt a product with an interrupted supply history.
• Competition from familiar IV PCA pumps.
• Limited use outside postoperative hospital care.
• Opioid stewardship and tighter hospital controls.
• The need to train nurses, pharmacists, and patients.
• Higher product complexity compared with injectable fentanyl.
• Limited reimbursement differentiation.

The redesigned product gained FDA approval in 2015, but the relaunch did not produce durable commercial scale. The subsequent 2017 recall removed the product from the market before it could establish a stable hospital franchise.

What was the financial trajectory of IONSYS?

IONSYS was never a major revenue driver for The Medicines Company. The company’s financial performance was dominated by other assets, including Angiomax, Orbactiv, and Kengreal. IONSYS remained a small product within the portfolio and did not materially offset the cost of acquisition, relaunch, manufacturing, and post-market support.

Period	Financial trajectory
2006 to 2008	Early commercialization was interrupted by recall and withdrawal
2008 to 2014	No sustained U.S. product revenue
2011 onward	The Medicines Company invested in acquisition, development, and relaunch activities
2015 to 2016	Revenue returned after FDA approval of the redesigned system, but remained limited
2017	Recall ended the relaunch and eliminated the prospect of meaningful recurring revenue
After 2017	No durable product revenue or established market franchise

Public company filings did not present IONSYS as a material standalone revenue contributor. The product’s economic burden extended beyond lost sales. The Medicines Company also faced costs associated with development, manufacturing qualification, inventory, quality remediation, regulatory work, and commercial infrastructure.

The acquisition of Incline Therapeutics gave The Medicines Company control of a differentiated hospital analgesic product, but the transaction did not translate into a durable growth asset. IONSYS illustrates the financial risk of a drug-device product in which commercial value depends on reliable hardware manufacturing and hospital workflow adoption.

Which companies challenged IONSYS commercially?

No approved generic product directly displaced IONSYS through an Abbreviated New Drug Application. The principal competitive threat came from established treatment modalities and hospital suppliers.

Competing option	Competitive advantage over IONSYS	Limitation
Intravenous fentanyl injection	Low cost, familiar, widely available	Requires IV access and staff administration
IV patient-controlled analgesia pump	Established hospital workflow	Requires pump, IV line, and monitoring
Oral opioids	Low cost and simple administration	Less suitable for patients unable to take oral drugs
Nurse-administered injectable opioids	Familiar and flexible	Higher staff workload
Epidural analgesia	Strong analgesic efficacy in selected procedures	More invasive and technically demanding
Other transdermal systems	Potentially simpler use	Usually slower or less suitable for acute postoperative dosing

The absence of a direct generic did not protect the product from substitution. Hospitals evaluate total workflow cost, nursing time, adverse-event risk, procurement reliability, and implementation burden. On these measures, IONSYS faced a difficult comparison with standard IV opioid protocols.

What generic entry risks existed for IONSYS?

The risk of a conventional generic was moderate from a legal perspective but low from a commercial perspective.

A generic applicant would have faced several technical and regulatory challenges:

• Demonstrating equivalent fentanyl delivery from a complex drug-device system.
• Matching activation, lockout, and dose limits.
• Showing consistent performance across skin types and application conditions.
• Establishing device reliability over the labeled shelf life.
• Addressing human-factors requirements.
• Reproducing or designing around system-specific features.
• Meeting opioid-control and hospital-use requirements.

At the same time, the product’s market was too small and commercially uncertain to create an attractive generic opportunity. A competitor could obtain better economics by developing a different delivery system or supplying conventional injectable fentanyl.

How did IONSYS compare with competing fentanyl delivery products?

IONSYS had a differentiated administration route but a narrow use case. It was not positioned to compete broadly with long-acting fentanyl patches, which are used for chronic pain and have materially different pharmacokinetics and safety profiles.

Attribute	IONSYS	Fentanyl transdermal patch	IV fentanyl PCA
Main use	Acute postoperative pain	Chronic persistent pain in opioid-tolerant patients	Acute postoperative and inpatient pain
Delivery speed	Controlled, short-term dosing	Slow continuous delivery	Rapid, adjustable dosing
Setting	Hospital	Outpatient and chronic-care settings	Hospital
Device complexity	High	Moderate	Moderate to high
Need for IV access	No	No	Yes
Commercial reach	Narrow	Broader chronic-pain market	Broad hospital use
Main risk	Device reliability and opioid exposure	Accumulation and misuse	Line, pump, and programming errors

The product’s strongest differentiation was the ability to provide patient-controlled fentanyl without an IV line. Its weakest commercial attribute was the limited number of patients and institutions for which that benefit justified a specialized device.

What licensing and transaction history affected IONSYS?

The principal strategic transaction was The Medicines Company’s acquisition of Incline Therapeutics in 2011. Incline had developed the next-generation IONSYS system after the earlier product’s withdrawal. The acquisition placed the product within a company experienced in hospital therapeutics and provided capital for regulatory resubmission and relaunch.

The transaction created value only if the redesigned product could achieve reliable manufacturing and hospital adoption. The later recall reduced the value of the acquired asset and limited the likelihood of further licensing or partnering activity.

There is no established post-recall licensing market for IONSYS. Any future commercial program would likely require a new sponsor, a redesigned device, new manufacturing controls, and a fresh commercial strategy rather than a simple relaunch of the historical product.

What is the current market outlook for IONSYS?

The current U.S. market outlook is effectively inactive. IONSYS has no meaningful revenue base, no established hospital purchasing channel, and no visible generic competition. A future product using the same general concept would need to demonstrate a clear advantage over IV PCA, injectable fentanyl, and newer postoperative pain protocols.

Potential demand could exist in hospitals seeking:

• Needle-free postoperative analgesia.
• Reduced dependence on IV access.
• Simplified patient-controlled dosing.
• Alternatives for selected short-stay surgical patients.

Commercial barriers remain substantial. The product would need high device reliability, competitive acquisition cost, simple staff training, and a strong quality history. A new entrant would also face opioid safety scrutiny and hospital budget pressure.

Key Takeaways

• IONSYS was a hospital-only iontophoretic fentanyl system for acute postoperative pain.
• FDA approval came in 2006, followed by a 2008 recall and withdrawal.
• The Medicines Company acquired Incline Therapeutics in 2011 and relaunched a redesigned system after FDA approval in 2015.
• A further recall in 2017 ended the commercial relaunch.
• IONSYS did not face a conventional generic launch; its main competition was IV fentanyl, PCA pumps, oral opioids, and standard hospital analgesia protocols.
• The product generated limited financial value and was not a material revenue contributor to The Medicines Company.
• Patent protection covered delivery technology and device features, but it did not overcome manufacturing and adoption problems.
• The current U.S. market is commercially inactive, with no durable revenue trajectory or established generic threat.

FAQs About IONSYS Market Dynamics and Financial Performance

Is IONSYS still available in the United States?

No. IONSYS has not maintained an active U.S. commercial market following the 2017 recall and subsequent discontinuation.

Did IONSYS have a generic competitor?

No approved generic IONSYS product became a meaningful commercial competitor. Hospitals substituted conventional fentanyl injections, IV PCA systems, and other analgesic approaches.

Why did The Medicines Company acquire IONSYS?

The acquisition gave The Medicines Company access to a differentiated hospital analgesic product with potential to reduce the need for IV access in postoperative patients. The expected value was undermined by later device and manufacturing problems.

Was IONSYS protected by a fentanyl patent?

No broad active-ingredient protection was available for fentanyl. The relevant intellectual property concerned iontophoretic delivery, device design, dose control, and manufacturing technology.

Could a redesigned IONSYS product return to the market?

A return would require a new sponsor or commercial partner to establish reliable manufacturing, satisfy FDA combination-product requirements, generate hospital demand, and overcome the product’s prior recall history.

References

1. U.S. Food and Drug Administration. (2006). IONSYS fentanyl iontophoretic transdermal system prescribing information. FDA.

2. U.S. Food and Drug Administration. (2015). FDA approves new IONSYS fentanyl iontophoretic transdermal system. FDA.

3. U.S. Food and Drug Administration. (2017). The Medicines Company issues voluntary recall of IONSYS fentanyl iontophoretic transdermal system. FDA.

4. The Medicines Company. (2011). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. The Medicines Company. (2016). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

6. The Medicines Company. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.